First Wave Biopharma, headquartered in Boca Raton, Florida, develops nonsystemic therapies for gastrointestinal diseases and went public in October 2016. Its key programs include latiglutenase, capeserod, and adrulipase.
ENTO has been in the news recently: ENTO is expanding its capabilities in managing clinical trials through the integration of BioPharma Services and Canadian Phase Onward, allowing for oversight of over 2,200 trials. Additionally, Accord BioPharma has received FDA approval for its biosimilar HERCESSI, which targets HER2 cancers and is set to launch in early 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
